Perfusion Systems Market Development | Industry Report 2021

The perfusion systems market is segmented on the basis of type (namely cardiopulmonary perfusion systems, ex vivo organ perfusion systems, and cell perfusion systems) and region.

The perfusion systems market is segmented on the basis of type (namely cardiopulmonary perfusion systems, ex vivo organ perfusion systems, and cell perfusion systems) and region.
Perfusion systems are used to bypass cardiopulmonary systems in order to treat patients with cardiac and respiratory diseases surgically. Perfusion systems such as heart-lung machines deliver oxygen and remove carbon dioxide in patients when the heart and lungs fail to carry out the process of blood oxygenation. With the increasing prevalence of cardiovascular and respiratory diseases across the globe, the use of perfusion systems is expected to rise in the coming years.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=164273069

Perfusion Systems Market Drivers
• Increasing prevalence of cardiovascular and respiratory diseases
• Rising number of organ transplantations
• Growth in Aging Population, Increasing Incidence of Multiple Organ Failures
• Government and NGO Initiatives to Encourage Organ Donation
• Increasing Investments in Cell-Based Research
• Increase in Biologic Manufacturing
Restraints
• High Cost of Organ Transplantation
• Ethical Concerns and High Cost of Cell-Based Research
Opportunities
• Increasing Pharmaceutical Research in Emerging Markets
• Rising Preference for Continuous Manufacturing
Challenges
• Organ Supply-Demand Gap

Increasing prevalence of cardiovascular and respiratory diseases
Cardiovascular diseases are among the leading causes of death globally. They account for about 9.4 million deaths every year. According to the WHO, in 2012, 17.5 million CVD-related deaths (31%) were reported across the globe; this number is expected to grow to more than 23.6 million by 2030. Their high prevalence is in part attributed to the rising prevalence of hypertension, a key risk factor for cardiovascular disease and strokes. In 2013, globally, it was estimated that about 1 billion people suffered from hypertension—a global prevalence of 40%. During the same year, the prevalence of hypertension among adults in Africa was 46% (highest worldwide), while in the Americas, the figure was 35% (the lowest) [Source: WHO]. Similarly, according to the WHO, chronic obstructive pulmonary disease (COPD) caused about 3 million deaths (5%) of the total deaths in 2015. COPD is expected to increase in the coming years due to increasing tobacco consumption and growing pollution.

Get Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=164273069

Major Market Developments:
• In January 2015, Medtronic acquired Covidien plc. (Ireland), a manufacturer of healthcare products for use in clinical and home settings worldwide. This acquisition aims to strengthen Medtronic’s customer base and resolve healthcare challenges with constant product development and imbibing new technologies.
• In October 2015, Sorin merged with Cyberonics Inc (US) to form a global medical technology company—LivaNova PLC (U.K.).
• In February 2014, Sorin acquired Bioengineering Laboratories S.p.A. (BEL), a manufacturer of cardiac surgery cannulas. This acquisition is expected to strengthen Sorin’s position in the cardiovascular cannulas market segment.
• In September 2016, Terumo partnered with CytoSorbents Corporation (US), a manufacturer of the CytoSorb extracorporeal blood purification adsorber. Under this partnership, Terumo commercialized the CytoSorb extracorporeal blood purification adsorber for cardiac surgery applications in France, Sweden, Denmark, Norway, Finland, and Iceland.

Global Perfusion Systems Market - Major Growth Strategies Adopted by Key Players

The global perfusion systems market is segmented on the basis of type and region. By type, the market is segmented into cardiopulmonary perfusion systems, cell perfusion systems, and ex vivo organ perfusion systems. The perfusion systems market is projected to reach USD 1,198.8 million by 2021 from USD 989.4 million in 2016, at a CAGR of 3.9% from 2016 to 2021.

This market is highly fragmented with different key players for the different types of perfusion systems. The major players in the cardiopulmonary perfusion systems market include Getinge AB (Sweden), Medtronic plc (Ireland), LivaNova PLC (U.K.), Terumo Corporation (Japan), and XENIOS AG (Germany). The major players in the ex vivo organ perfusion systems market are Lifeline Scientific, Inc. (U.S.) and XVIVO Perfusion AB (Sweden), while, Repligen Corporation (U.S.), Spectrum Laboratories, Inc. (U.S.), Merck KGaA (Germany), Harvard Bioscience, Inc. (U.S.), and ALA Scientific Instruments, Inc. (U.S.) are some of the leading players in the cell perfusion systems market.

Key players adopted strategies such as partnerships, collaborations, joint ventures, agreements, mergers & acquisitions, approvals, product launches, and expansions to maintain and enhance their position in the market.

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=164273069

Partnerships, collaborations, joint ventures, agreements, and mergers & acquisitions accounted for 28.6% of the all strategic developments from 2013 to 2016. Players adopted this strategy to strengthen their distribution networks, expand their research network, and enhance their market reach & customer base. In 2015, Getinge AB partnered with iMDsoft GmbH to integrate its data management systems into Getting’s heart-lung machines, blood/gas monitors, and heater-cooler units. Similarly, in 2015, Sorin and Cyberonic merged to form LivaNova PLC. The key players that adopted these strategies were Getinge AB, Medtronic plc, LivaNova PLC, Terumo Corporation, and XENIOS AG.

Product launches accounted for 21.9% of strategic developments in the market from 2013 to 2016. This strategy was employed by players to enhance their product portfolios. In 2015, Medtronic plc launched Affinity CP Centrifugal Blood Pump in Brazil. Similarly, LivaNova PLC launched Flextherm— heating and cooling systems in 2015. In 2016, Terumo Corporation launched the CAPIOX FX Advance oxygenator. Medtronic plc, LivaNova PLC, Lifeline Scientific, Inc., XVIVO Perfusion AB, Repligen Corporation, and Terumo Corporation were the key players who adopted this strategy.

Sample of the Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=164273069 
Approvals accounted for 16.2% of total strategic developments in the perfusion systems market from 2013 to 2016. This strategy was adopted by players to strengthen their product offerings and widen their product distribution network. In 2014, XENIOS received the CE approval for its MiniLung Petite Membrane Ventilator, MiniLung Membrane Ventilator, and iLA Membrane Ventilator. Similarly, in 2015, Lifeline Scientific received the Chinese Food and Drug Administration (CFDA) approval for its LifePort Kidney Transporter device. In 2015, XVIVO received approval for the clinical use of XPS in Canada. The key players that adopted this strategy were XENIOS AG, Lifeline Scientific, Inc., and XVIVO Perfusion AB.

Expansions accounted for 12.4% of key growth strategies adopted by players in the market from 2013 to 2017. This strategy was used by key players to strengthen their distribution networks, increase their global presence, and cater to the needs of their growing customer base. For instance, Lifeline Scientific opened a new facility in Brazil in 2015, to expand its geographic reach. Similarly, in 2017, Terumo opened a new branch for its operations in Myanmar. XENIOS AG, Medtronic plc, Terumo Corporation, MicroPort Scientific Corporation, and Lifeline Scientific, Inc. are the key players that adopted this strategy.

Other strategies such as rebranding, website launch, product deployment, and market development accounted for 21.0% of the total developments. The key players that adopted these strategies were Terumo Corporation, LivaNova PLC, XENIOS AG, and Lifeline Scientific, Inc.